A novel packaging system of recombinant AAV5/5 vector

Shengwu Gongcheng Xuebao/Chinese Journal of Biotechnology

Volumn 26, Issue 5, 2010, Pages 679-686

  Dong, Xiaoyan ^a,b,c   Tian, Wenhong ^a   Yuan, Zhenhua ^a   Tan, Shuping ^a   Wu, Xiaobing ^a  

^a CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^b FUDAN UNIVERSITY   (China)

^c Beijing Fiveplus Molecular Medicine Institute   (China)

Author keywords

Adeno associated virus type 5 (AAV5); Herpes simplex virus I; Production system; Virus vector

Indexed keywords

VIRUS PROTEIN;

ADENO ASSOCIATED VIRUS; ARTICLE; CELL STRAIN HEK293; GENE THERAPY; GENE VECTOR; GENETIC REASSORTMENT; GENETIC RECOMBINATION; GENETICS; HERPES SIMPLEX VIRUS 1; HUMAN; PHYSIOLOGY; VIRUS ASSEMBLY;

DEPENDOVIRUS; GENE THERAPY; GENETIC VECTORS; HEK293 CELLS; HERPESVIRUS 1, HUMAN; HUMANS; REASSORTANT VIRUSES; RECOMBINATION, GENETIC; VIRAL PROTEINS; VIRUS ASSEMBLY;

ADENO-ASSOCIATED VIRUS; HERPES; HUMAN HERPESVIRUS 1; MIRIDAE;

EID: 77954764696     PISSN: 10003061     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Wu ZJ, Asokan A, Samulski RJ. Adeno-associated virus serotypes: vector toolkit for human gene therapy. Mol Ther, 2006, 14(3): 316-327.
2. Walters RW, Yi SMP, Keshavjee S, et al. Binding of adeno-associated virus type 5 to 2,3-linked sialic acid is required for gene transfer. J Biol Chem, 2001, 276(23): 20610-20616.
3. Pasquale GD, Davidson BL, Stein CS, et al. Identification of PDGFR as a receptor for AAV5 transduction. Nat Med, 2003, 9(10): 1306-1312.
4. Rabinowitz JE, Rolling F, Li CW, et al. Cross-packaging of a single Adeno-associated virus(AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity. J Virol, 2002, 76(2): 791-801.
5. Cunningham C, Davison AJ. A cosmid-based system for constructing mutants of herpes simplex virus type 1. Virology, 1993, 197(1): 116-124.
6. Wu XB, Dong XY, Wu ZJ, et al. A novel method for purification of recombinant adeno-associated virus vectors on a large scale. Chin Sci Bull, 2001, 46(6): 485-489.
7. Choi VW, McCarty DM, Samulski RJ. AAV hybrid serotypes: improved vectors for gene delivery. Curr Gene Ther, 2005, 5(3): 299-310.
8. Xiao X, Li J, Samulski RJ. Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus. J Virol, 1998, 72(3): 2224-2232.
9. Wu ZJ, Wu XB, Hou YD. Construction of a recombinant herpes simplex virus which can provide packaging function for recombinant adeno-associated virus. Chin Sci Bull, 1999, 44(8): 715-719.
10. Yan H, Guo Y, Zhang P, et al. Superior neovascularization and muscle regeneration in ischemic skeletal muscles following VEGF gene transfer by rAAV1 pseudotyped vectors. Biochem Biophys Res Commun, 2005, 336(1): 287-298.
11. Han G, Wang R, Chen G, et al. Gene delivery GAD500 autoantigen by AAV serotype 1 prevented diabetes in NOD mice: transduction efficiency do not play important roles. Immunol Lett, 2008, 115(2): 110-116.
12. Klein RL, Dayton RD, Leidenheimer NJ, et al. Efficient neuronal gene transfer with AAV8 leads to neurotoxic levels of tau or green fluorescent proteins. Mol Ther, 2006, 13(3): 517-527.
13. Lipshutz GS, Titre D, Brindle M, et al. Comparison of gene expression after intraperitoneal delivery of AAV2 or AAV5 in utero. Mol Ther, 2003, 8(1): 90-98.
14. Wustner JT, Arnold S, Lock M, et al. Production of recombinant adeno-associated type 5(rAAV5) vectors using recombinant herpes simplex viruses containing rep and cap. Mol Ther, 2002, 6(4): 510-518.